Literature DB >> 22955682

[The use of frozen sections in the handling of soft tissue tumors].

G Amann1, B Liegl-Atzwanger.   

Abstract

Due to the multiplicity of localizations and entities, handling of soft tissue tumors is a very challenging subject requiring intensive interdisciplinary collaboration. With respect to the use of intraoperative frozen sections, the following facts are of special relevance: 1) the usual criteria for malignancy, such as infiltrative growth and high mitotic rate are only restrictedly applicable to soft tissue tumors. 2) Correct diagnosis of the tumor entity often requires not only the use of immunohistochemistry but also the identification of genetic alterations by the polymerase chain reaction and/or fluorescence in situ hybridization. In many centres, 14G core biopsies taken from different tumor areas represent the preferred method for a diagnostic biopsy. Apart from cryocollection additional frozen section investigations are used especially in case of open biopsies for quality control of the submitted material or in cases of excision biopsies to ascertain a highly probable radiological diagnosis. The use of intraoperative frozen sections to clarify the resection margins is generally undisputed but should definitely be restricted to centres specialized and experienced in the handling of soft tissue tumors.

Entities:  

Mesh:

Year:  2012        PMID: 22955682     DOI: 10.1007/s00292-012-1606-8

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  22 in total

Review 1.  Musculoskeletal neoplasms: biopsy and intervention.

Authors:  Ambrose J Huang; Susan V Kattapuram
Journal:  Radiol Clin North Am       Date:  2011-11       Impact factor: 2.303

2.  Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas.

Authors:  R U Ashford; S W McCarthy; R A Scolyer; S F Bonar; R Z Karim; P D Stalley
Journal:  J Bone Joint Surg Br       Date:  2006-09

Review 3.  Practical issues of intraoperative frozen section diagnosis of bone and soft tissue lesions.

Authors:  Marilyn M Bui; Prudence Smith; Samuel V Agresta; David Cheong; G Douglas Letson
Journal:  Cancer Control       Date:  2008-01       Impact factor: 3.302

Review 4.  Biopsy of soft tissue masses: evidence-based medicine for the musculoskeletal tumor society.

Authors:  Bruce T Rougraff; Albert Aboulafia; J Sybil Biermann; John Healey
Journal:  Clin Orthop Relat Res       Date:  2009-07-14       Impact factor: 4.176

5.  Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy.

Authors:  Gunar K Zagars; Matthew T Ballo; Peter W T Pisters; Raphael E Pollock; Shreyaskumar R Patel; Robert S Benjamin
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

6.  Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study.

Authors:  Nina L Jebsen; Clement S Trovik; Henrik C F Bauer; Anders Rydholm; Odd R Monge; Kirsten Sundby Hall; Thor Alvegård; Oyvind S Bruland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-22       Impact factor: 7.038

7.  Fine-needle aspiration cytology, frozen section, and open biopsy: relative significance in diagnosis of musculoskeletal tumors.

Authors:  Maninder Singh Shah; Vishal Garg; Sudhir K Kapoor; B K Dhaon; Ranjana Gondal
Journal:  J Surg Orthop Adv       Date:  2003

8.  Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients.

Authors:  P Gustafson; K E Dreinhöfer; A Rydholm
Journal:  Acta Orthop Scand       Date:  1994-02

Review 9.  Pathology of soft tissue sarcoma.

Authors:  Brian P Rubin; John R Goldblum
Journal:  J Natl Compr Canc Netw       Date:  2007-04       Impact factor: 11.908

Review 10.  Application of immunohistochemistry to soft tissue neoplasms.

Authors:  Josefine Heim-Hall; Sophia L Yohe
Journal:  Arch Pathol Lab Med       Date:  2008-03       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.